Ng Grace, Roberts Ian, Coleman Nicholas
Medical Research Council, Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge, United Kingdom.
Diagn Mol Pathol. 2005 Dec;14(4):203-12. doi: 10.1097/01.pas.0000177801.60121.05.
A common aim in cancer research is to investigate mechanisms of malignant progression by genetic analysis of key stages, including pre-malignancy, microinvasion, and micrometastases. As such lesions are small and require microdissection from clinical samples, the amount of DNA that can be recovered is limited and frequently inadequate for commonly used techniques of genomic analysis, such as comparative genomic hybridization (CGH). There is a critical requirement for techniques of whole-genome amplification that minimize representation bias in the amplified sample. Several techniques have been described, although their relative suitability for CGH has not been examined adequately. Here we compare the abilities of degenerate oligonucleotide-primed PCR (DOP-PCR), multiple-strand displacement amplification (MDA), and balanced PCR accurately to amplify limited amounts of template DNA for use in CGH. Amplification by DOP-PCR and MDA, but not balanced PCR faithfully preserved the original genomic content following amplification, as evidenced by generally concordant CGH copy number karyograms. Whereas the amplification products of DOP-PCR were immediately available for labeling and hybridization, the products of MDA required a further digestion step to produce optimal-sized probes for CGH. Moreover, MDA was less reliable overall than DOP-PCR at the lowest starting amount of 10 pg of template DNA. We conclude that DOP-PCR is the method of choice for whole-genome amplification of minute quantities of DNA to enable global genomic analysis to be performed on limited clinical samples.
癌症研究的一个共同目标是通过对关键阶段(包括癌前病变、微浸润和微转移)进行基因分析,来研究恶性进展的机制。由于这些病变很小,需要从临床样本中进行显微切割,因此能够回收的DNA量有限,常常不足以用于常用的基因组分析技术,如比较基因组杂交(CGH)。对于全基因组扩增技术有着迫切需求,这类技术能将扩增样本中的代表性偏差降至最低。虽然已经描述了几种技术,但它们对CGH的相对适用性尚未得到充分研究。在这里,我们比较了简并寡核苷酸引物PCR(DOP-PCR)、多链置换扩增(MDA)和平衡PCR准确扩增有限量模板DNA以用于CGH的能力。DOP-PCR和MDA扩增,但平衡PCR扩增后不能忠实地保留原始基因组内容,这从通常一致的CGH拷贝数核型图可以证明。DOP-PCR的扩增产物可立即用于标记和杂交,而MDA的产物需要进一步消化步骤才能产生用于CGH的最佳大小的探针。此外,在最低起始量为10 pg模板DNA时,MDA总体上不如DOP-PCR可靠。我们得出结论,DOP-PCR是对微量DNA进行全基因组扩增的首选方法,以便能够对有限的临床样本进行全基因组分析。